Cardiovascular and inflammatory therapies

CVasThera is a biopharmaceutical company focused on enhancing drug development processes to improve patient outcomes. Founded in 2016 by seasoned professionals in the pharmaceutical industry, the company emphasizes a comprehensive approach to drug discovery and development. Their expertise lies in integrating biological, chemical, and pharmacological data to innovate and streamline the early stages of drug development. This includes a commitment to adaptive clinical protocols that allow for more flexible and efficient evaluations of drug candidates, ultimately aiming to achieve faster proof-of-concept milestones.

The company operates on a business model that prioritizes access to scientific expertise, funding, and intellectual property strategies. By fostering independent research and reducing financial barriers, CVasThera aims to accelerate innovation in early-stage drug development. Their portfolio includes promising projects targeting conditions such as atrial fibrillation, acute myocardial infarction, and Crohn's disease, showcasing their dedication to transforming identified compounds into effective therapeutics. Through collaboration with global partners and a focus on creating value together, CVasThera is positioned to make significant contributions to the field of biopharmaceuticals.

France

CVasThera is a early clinical-stage biopharmaceutical company focused on developing novel therapies designed to change the standard of care for cardiovascular and bowel pathologies.

CVASTHERA

Company Details